SYS6026 for advanced solid tumors with HPV infection
Part of Cancer clinical trials.
This trial tests a new combination therapy for advanced solid tumors that have HPV type 16 or 18. It aims to see if the treatment is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your tumor must have HPV type 16 or 18.
- Your cancer must be advanced or spread and cannot be removed by surgery.
- You must be well enough to be up and about (ECOG 0 or 1).
- Your major organs (like liver, kidneys, blood counts) must be working well.
- If you are of childbearing age, you must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine (SYS6026) for women with high-grade cervical lesions caused by HPV type 16 or 18. It aims to see if the vaccine can help the body clear these precancerous cells, potentially avoiding surgery.
This trial tests whether adding a new drug called SYS6006 to an existing cancer treatment (enlonstobart) works better than enlonstobart alone for advanced solid tumors that cannot be surgically removed. The goal is to see if the combination helps shrink tumors and improve survival.
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.